Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 307 results found since Jan 2013.
FDA Advisory Panel Supports Novel Drug Coated Balloon
The FDA’s Circulatory System Devices advisory panel voted unanimously on Thursday to support approval of CR Bard’s Lutonix Drug Coated Balloon. … Click here to read the full post on Forbes.
Source: CardioBrief - June 13, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events CR Bard drug coated balloon FDA peripheral arterial disease Source Type: blogs
Medtronic’s CoreValve Gains New Indication For High Risk Patients
Medtronic’s CoreValve system today gained a second indication from the FDA for use in patients with severe aortic stenosis who are at high risk for surgery. … Click here to read the full post on Forbes.
Source: CardioBrief - June 12, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics aortic valve replacement CoreValve Edwards Medtronic Sapien TAVR Source Type: blogs
Major Medical Organizations Establish Ambitious Diabetes Registry
Our knowledge of diabetes today is a bit like the way blind men understand an elephant. With a myriad of isolated perspectives it’s nearly impossible to gain a broad overview. Now, a new initiative from a group of major medical organization will seek to provide the tools to better see a full picture of the elephantine problem of diabetes. The American College of Cardiology, the American Diabetes Association, the American College of Physicians, and the Joslin Diabetes Center announced today that they will launch the Diabetes Collaborative Registry, which they say is “aimed at tracking and improving the More…
Source: CardioBrief - June 10, 2014 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes diabetes PINNACLE registries Source Type: blogs
Wide Range In Cancer Risk From Radiation In Children Undergoing Heart Surgery
Children with heart disease are at increased risk for developing cancer later in life due to their exposure to radiation during imaging procedures. Since an ever-growing number of children with heart disease now reach adulthood, this may become an increasingly important public health issue. A new study published in Circulation offers some reassurance in finding that for most children the increased risk is low or negligible. But for some children who undergo more complex procedures, the increased risk is significant. … Click here to read the entire story on Forbes.
Source: CardioBrief - June 9, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes Source Type: blogs
Prescription Delay Following Stent Implantation Is a Common and Deadly Problem
After receiving a stent, many patients delay or fail to fill their prescription for clopidogrel or another antiplatelet agent. Now, a study published in the Journal of the American Heart Association offers evidence that this problem is widespread and often leads to serious consequences. Researchers analyzed data from all stent implantations performed in British Columbia from 2004 through 2006. In all, 15,629 stents were implanted: 3,599 patients received at least one drug-eluting stent (DES), and 12,030 received bare metal stents (BMS) alone. Nearly a third of the patients in each stent group did not fill their prescr...
Source: CardioBrief - May 28, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics clopidogrel compliance prescriptions stents Source Type: blogs
The Walking Dead: Renal Denervation In Europe Just Can’t Be Stopped
Earlier this year the only large, well-designed trial of renal denervation– the once highly-promising catheter-based technology that was widely expected to “cure” difficult cases of resistant hypertension– failed spectacularly. Many hypertension experts believe that ultimately the technique will prove to be beneficial, but after the failure of Simplicity HTN-3 it is clear that there’s a great deal of research that needs to be performed to find out just how– or if– this novel technology should be used. In the US this does not present a problem. The FDA has not approved renal dener...
Source: CardioBrief - May 21, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics hypertension Medtronic renal denervation st jude medical Source Type: blogs
Medtronic To Pay Over $1Billion To Settle Patent Litigation With Edwards Lifesciences
After years of protracted and often bitter litigation in the US and abroad, Edwards Lifesciences and Medtronic today announced a broad resolution to all their patent disputes over transcatheter heart valves. Medtronic will pay more than a billion dollars over the course of the agreement, which lasts until April 2022. … Click here to read the full post on Forbes.
Source: CardioBrief - May 20, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics CoreValve Edwards Lifesciencences Medtronic patents Sapien TAVR Source Type: blogs
Routine Shock Testing Not Required During ICD Implantation
When cardiologists implant defibrillators in patients at high risk of dying from a heart rhythm disorder they nearly always perform a defibrillation test in which they induce a lethal arrhythmia, ventricular fibrillation, to make sure the device accurately detects the arrhythmia and terminates it with an appropriate shock. But routine defibrillation testing has never been shown to be safe or necessary. In recent years some experts have maintained that routine defibrillation testing may not be necessary. Now a new study, presented yesterday at the Heart Rhythm Society meeting in San Francisco, offers evidence that although More…
Source: CardioBrief - May 9, 2014 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms defibrillation testing ICD implantation ICDs Source Type: blogs
What Role Should Coca-Cola Play In Obesity Research?
What role should Coca-Cola and other food and beverage companies play in funding and communicating research about nutrition and obesity? The question is prompted by a recent article in the Journal of the American College of Cardiology. The “state-of-the-art” paper reviews the relationship of obesity and cardiovascular disease and presents the case that a decline in physical activity is the primary cause of the obesity epidemic. The article downplays the role of calories and diet and does not include the words “sugar,” “soda,” or “beverage.” Three of the five authors...
Source: CardioBrief - April 27, 2014 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Source Type: blogs
New Study Lends Support For Alternative Heart Attack Treatment Strategy
It is generally agreed that the best treatment for heart attack patients is to immediately reperfuse the blocked artery with a stent. But many people live in areas where this strategy, known as primary PCI, is not available within the time frame when it produces the greatest benefit. Previous studies have found good short term outcomes in patients who receive a pharmaco-invasive strategy, in which patients first receive fibrinolytic therapy including a clot-busting drug and then later undergo angiography. Now long-term results from a large real-world study show that this strategy may be an acceptable alternative for More…
Source: CardioBrief - April 22, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery MI/ACS clot busters heart attack primary PCI STEMI stents Source Type: blogs
Will Edwards Snatch Defeat From The Jaws Of Its Victory Over Medtronic?
On the heels of a sweeping victory in the courts over its rival Medtronic, Edwards Lifesciences is poised to dominate the TAVR (transcatheter aortic valve replacement) market– the revolutionary new catheter technology that offers some patients with life-threatening aortic valve disease an alternative to chest-splitting surgery. Although the legal wrangling is not quite over– Medtronic is appealing the decision and has requested that enforcement of the injunction be postponed– it appears likely that Edwards will ultimately achieve a broad legal and business victory. But Edwards’ unprecedented ...
Source: CardioBrief - April 21, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Edwards injunction litigation Medtronic patents TAVR Source Type: blogs
New Medtronic Heart Valve Threatened By Court Decision
A legal injunction may severely limit the availability in the United States of Medtronic’s CoreValve device, which only received FDA approval earlier this year. The device received abundant praise recently when a large clinical trial demonstrated substantial advantages for CoreValve over traditional open-heart surgery. The injunction is the latest episode in an ongoing patent war in which Edwards Lifesciences, which pioneered the field of transcatheter aortic valve replacement with its Sapien devices, has sought to hinder Medtronic from competing in the US and international markets. … Click here to read...
Source: CardioBrief - April 15, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics CoreValve Edwards Lifesciences Corporation Medtronic patents Sapien TAVR Source Type: blogs
The Uncertain Future Of A Once Highly Promising Device For Lowering Blood Pressure
Following the spectacular crash and burn of the Symplicity HTN-3 trial at the American College of Cardiology two weeks ago, the future of renal denervation (RDN)– the once highly promising catheter technology that many thought would cure resistant hypertension– appears in doubt. Although the device has not been approved in the US– and will not be approved without further clinical trials– in Europe and other places it remains on the market. So the questions about the technology’s future revolve around the future direction of research in the field and how the existing renal denervation mark...
Source: CardioBrief - April 14, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics blood pressure Boston Scientific hypertension Medtronic renal denervation resistant hypertension Source Type: blogs
Cardiology And The Medicare Data Avalanche
The avalanche of data released by Medicare on Wednesday was followed shortly by an avalanche of news reports about the data. Here’s a review of some of the more significant cardiology-related details that came out in these stories. Cardiology was the third in a New York Times list of total Medicare payments received by the highest-paid 2% of doctors. This 2% accounted for nearly one-fourth of total Medicare payments. There were 2,176 cardiologists in the top 2% group and they received more than 1.6 billion dollars from Medicare. Ahead of cardiologists at the top of the list were ophthalmologists More…
Source: CardioBrief - April 10, 2014 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Source Type: blogs
Aspirin and Clonidine Fail to Help Surgery Patients
Heart attacks (myocardial infarctions) are among the most common and serious side effects of noncardiac surgery. An effective regimen to minimize this risk has been the subject of considerable debate in recent years. The controversy was recently exacerbated because the recommendation to use beta-blockers in this setting was based on research which has now been discredited. Substantial evidence against the use of perioperative beta blockers came from the original POISE trial. Now a second POISE trial, the Perioperative Ischemic Evaluation 2 (POISE-2) trial, casts doubt on the value of two other proposed strategies to reduce More…
Source: CardioBrief - March 31, 2014 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes aspirin clonidine noncardiac surgery perioperative beta-blockade Source Type: blogs
